|1.||Heera, Jayvant: 9 articles (06/2015 - 01/2010)|
|2.||van der Ryst, Elna: 8 articles (06/2015 - 01/2005)|
|3.||Mayer, Howard: 7 articles (12/2010 - 10/2008)|
|4.||Westby, Mike: 7 articles (03/2010 - 01/2005)|
|5.||Goodrich, James: 6 articles (12/2010 - 10/2008)|
|6.||Clotet, Bonaventura: 5 articles (10/2015 - 10/2008)|
|7.||Fätkenheuer, Gerd: 5 articles (03/2015 - 10/2008)|
|8.||Nelson, Mark: 5 articles (01/2012 - 10/2008)|
|9.||Gulick, Roy M: 4 articles (10/2015 - 10/2008)|
|10.||Hoepelman, Andy I M: 4 articles (07/2015 - 10/2008)|
01/01/2007 - "Maraviroc is only effective against CCR5-tropic virus, which predominates throughout infection but is more common in patients at the early asymptomatic stage of infection."
05/01/2010 - "Further studies are required to assess the clinical efficacy of maraviroc in HIV-2 infection."
12/15/2010 - "Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2."
10/01/2014 - "In combination studies, R4.0, CCL5, and maraviroc exhibited concomitant interactions with CCR5 and promoted synergic inhibition of HIV-1 in acute-infection assays. "
02/01/2014 - "Maraviroc, a CCR5 antagonist blocking coreceptor binding during HIV entry, is active in vitro against CCR5-tropic HIV-2 but more studies are needed to validate its use in therapeutic treatments against HIV-2 infection. "
|2.||HIV Infections (HIV Infection)
12/01/2015 - "We used bone marrow/liver/thymus (BLT) humanized mice to establish the effect of semen on vaginal HIV infection and on the efficacy of topically applied maraviroc. "
01/01/2012 - "This article reviews the safety and efficacy of maraviroc in the treatment of HIV infection. "
10/23/2015 - "Single oral dose of maraviroc does not prevent ex-vivo HIV infection of rectal mucosa in HIV-1 negative human volunteers."
06/01/2015 - "The demonstration that individuals with a 32-bp deletion within the CCR5 locus were resistant to human immunodeficiency virus (HIV) infection, while those heterozygous for the mutation progressed more slowly, led to the discovery of maraviroc (MVC), a CCR5 antagonist. "
03/01/2015 - "Sixty-six patients started a maraviroc-containing cART with a history of HIV infection lasting 13.9±10.7 years. "
|3.||Acquired Immunodeficiency Syndrome (AIDS)
12/01/2010 - "The objective of this study was to predict the long-term clinical impact and cost-effectiveness of maraviroc in treatment-experienced adults with HIV/AIDS in Mexico. "
10/15/2007 - "The 48 week interim results of this trial using twice daily maraviroc were reported at the International AIDS Society meeting in July 2007. "
01/01/2014 - "Maraviroc, discovered as a CCR5 antagonist, is the only CCR5 inhibitor that has been approved by both US FDA and the European Medicines Agency (EMA) for treating HIV/AIDS patients. "
01/01/2012 - "However our modelling also indicates that administration of maraviroc as a monotherapy or with BT of suboptimal efficacy can promote emergence of X4 tropic virus, resulting in accelerated progression to AIDS. "
02/01/2009 - "Although one antagonist--maraviroc, a CCR5 inhibitor to treat AIDS--has been registered as an approved drug, this is the only success so far. "
07/01/2015 - "Combinations with maraviroc were effective in reducing inflammation, but data about immunological recovery are conflicting. "
01/01/2010 - "Maraviroc-treated patients had earlier, modest decreases in certain markers of immune activation and inflammation, although in this small study, many of the differences were not statistically significant. "
06/01/2014 - "Potential anti-inflammatory effects of maraviroc in HIV-positive patients: a pilot study of inflammation, endothelial dysfunction, and coagulation markers."
03/01/2013 - "These results support the additional immunological effects of CCR5 blockade and suggest that maraviroc might have potential capacity to inhibit HIV-associated chronic inflammation and activation, both by directly affecting T cell activation and by reducing entrapment of lymphocytes in lymph nodes."
05/28/2013 - "Therefore, maraviroc could benefit HIV-positive patients with residual chronic inflammation who are at a high risk of acute coronary disease despite a suppressive antiretroviral therapy. "
|5.||Immune Reconstitution Inflammatory Syndrome
11/01/2014 - "Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial."
01/30/2014 - "Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome."
11/27/2009 - "Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management?"
01/01/2014 - "Due to the lack of therapeutic options for patients with progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome (PML-associated IRIS), maraviroc has generated expectations among the medical community. "
03/01/2015 - "High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc."
|2.||CCR5 Receptors (CCR5 Receptor)
|2.||Hematopoietic Stem Cell Mobilization
|3.||Transplantation (Transplant Recipients)